ms. maxwell. you testified about the lack of transparency, to ensure that the 340b providers are not overpaying pharmaceutical manufacturers. what can we do to increase transparency, and ensure that overpayments are not occurring? >> thanks for that question. it is a really important one, and one that speaks to a number of our recommendations around transparency. we think the best way to provide better transparency is for hersa to share -- directly with providers as well as states. is there any reason that hersa is not doing that now? >> in terms of providers, hersa does have the authority that was granted in 27 with the aca. they have not completed their secure data system. my understanding that that is in progress. but it is not completed and may not be completed until the completion and effective date of the ongoing rules about suing -- ceiling price. in terms of sharing the information, that would require more authority from congress for hersa to be able to share that. >> thank you. i -- the a